The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2019 | CAR need an upgrade?
Although CAR T-cell therapy is a vast improvement on previous treatments, there is plenty of room for improvement. Speaking at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago, IL, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, Milwaukee, WI, discusses how the potential to target two antigens on non-Hodgkin lymphomas could further improve clinical outcomes.
